In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice to prescribers on how the treatment can be accessed and which patient groups are eligible to receive Wegovy®. The document explains some of the limitations of the treatment and the evidence base, as described by NICE and may help to manage patient expectations.

At the time of publication the product is not yet available in the UK.